BIOMAT Database Logo BIOMAT Database Logo

The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1. 2015

Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Center for Emerging and Reemerging Infectious Diseases and Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA smithra@u.washington.edu.

Treatment options for individuals infected with human immunodeficiency virus type 2 (HIV-2) are restricted by the intrinsic resistance of the virus to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and the reduced susceptibility of HIV-2 to several protease inhibitors (PIs) used in antiretroviral therapy (ART). In an effort to identify new antiretrovirals for HIV-2 treatment, we evaluated the in vitro activity of the investigational nucleoside analog BMS-986001 (2',3'-didehydro-3'-deoxy-4'-ethynylthymidine; also known as censavudine, festinavir, OBP-601, 4'-ethynyl stavudine, or 4'-ethynyl-d4T). In single-cycle assays, BMS-986001 inhibited HIV-2 isolates from treatment-naive individuals, with 50% effective concentrations (EC50s) ranging from 30 to 81 nM. In contrast, EC50s for group M and O isolates of HIV-1 ranged from 450 to 890 nM. Across all isolates tested, the average EC50 for HIV-2 was 9.5-fold lower than that for HIV-1 (64 ± 18 nM versus 610 ± 200 nM, respectively; mean ± standard deviation). BMS-986001 also exhibited full activity against HIV-2 variants whose genomes encoded the single amino acid changes K65R and Q151M in reverse transcriptase, whereas the M184V mutant was 15-fold more resistant to the drug than the parental HIV-2ROD9 strain. Taken together, our findings show that BMS-986001 is an effective inhibitor of HIV-2 replication. To our knowledge, BMS-986001 is the first nucleoside analog that, when tested against a diverse collection of HIV-1 and HIV-2 isolates, exhibits more potent activity against HIV-2 than against HIV-1 in culture.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857

Related Publications

Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
November 2013, Antimicrobial agents and chemotherapy,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.
May 2014, International journal of toxicology,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1.
December 1987, Antimicrobial agents and chemotherapy,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Structure-based design, synthesis, and in vitro assay of novel nucleoside analog inhibitors against HIV-1 reverse transcriptase.
August 2005, Bioorganic & medicinal chemistry letters,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
January 2016, The lancet. HIV,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
January 2014, Antiviral therapy,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates.
July 2022, AIDS (London, England),
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.
June 2014, Journal of clinical pharmacology,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
In vitro activities of nucleoside analog antiviral agents against salmonellae.
January 1993, Antimicrobial agents and chemotherapy,
Robert A Smith, and Dana N Raugi, and Vincent H Wu, and Sally S Leong, and Kate M Parker, and Mariah K Oakes, and Papa Salif Sow, and Selly Ba, and Moussa Seydi, and Geoffrey S Gottlieb, and
A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2.
July 1982, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!